Diagnostic Methods in Australia
In Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011, the Federal Court confirmed that diagnostic methods are patentable subject-matter in Australia. This will be a satisfying result for...
In Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011, the Federal Court confirmed that diagnostic methods are patentable...
Read More
China Government Releases New Regulation on Human Genetic Resource
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on July 1. For the life sciences industry and research organizations...
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on...
Read More
Will the United States Congress Clean-Up the Patent Eligibility Mess?
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter that has plagued the United States patent system in recent...
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter...
Read More
The “plausibility” threshold remains low in Australia
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical inventions and can be a hurdle for innovators even if...
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical...
Read More
Claim Drafting Tip: Written Description and Obviousness of Claims with Functional Features — Two Sides of the Same Coin
A recent precedential decision by the United States Federal Circuit (Nuvo Pharmaceuticals v DR. Reddy’s Laboratories (Fed Cir, No 17-2473, 15 May 2019) has provided valuable advice on the balance between...
A recent precedential decision by the United States Federal Circuit (Nuvo Pharmaceuticals v DR. Reddy’s Laboratories (Fed Cir, No 17-2473,...
Read More
Pharmaceutical patents: Fighting a $25 million claim for damages
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia will calculate damages in proceedings concerning the infringement of a...
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia...
Read More
New Zealand Update: ACTIPHEN Too Similar to ACTAZIN to Register
Anagenix opposed the Pharmazen’s application to register ACTIPHEN in connection with a range of medicinal food preparations (Class 5) and printed materials relating to those goods (Class 16).
Anagenix opposed the Pharmazen’s application to register ACTIPHEN in connection with a range of medicinal food preparations (Class 5)...
Read More